Median OS was 35.0 months in the enzalutamide-alone arm vs 42.3 months in the combination arm. The combination of enzalutamide (Xtandi) plus radium-223 (Ra223, Xofigo) for the treatment of metastatic ...

On Cox regression analysis, glycoproteins were predictive of PFS response to nivolumab plus cabozantinib vs sunitinib (P < .01). Serum glycoproteins involved in complement cascade and lipid metabolism ...

New findings from the open-label SPLASH trial show patients with mCRPC achieved improved progression-free survival as well as response rates and antigen-specific reductions. Prostate-specific membrane ...

“I think that these data in this approximately 700 patient trial consolidates and makes a strong case for the role of pembrolizumab in the adjuvant setting,” says Guru P. Sonpavde, MD. In this video, ...

“NKT2152 demonstrated robust anti-tumor activity in a heavily pretreated, high-risk advanced clear cell renal cell carcinoma population," said Eric Jonasch, MD. The investigational oral HIF-2α ...

“Today, we're presenting the results of this analysis, and we show that patients who have a high Decipher score derive significant benefit from docetaxel,” says Gerhardt Attard, MD, PhD, FRCP. In this ...

Investigators observed promising clinical effect with the EGFR / HER3 bispecific antibody-drug conjugate. Epidermal growth factor receptor (EGFR) / epidermal growth factor 3 (HER3) bispecific antibody ...

The results “support the prioritized development of TAR-200 monotherapy in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer," said Michiel van der Heijden, MD, PhD. Results ...

“The overall survival showed a 25% reduction in the risk of death. This is statistically significant,” said Thomas B. Powles, MBBS, MRCP, MD. Results of a large phase 3 study support the use of ...

According to the authors, “darolutamide significantly reduced the risk of radiological progression or death by 46%” (HR=0.54, 95% CI, 0.41-0.71, P < .0001). Results of the phase 3 ARANOTE study ...

At a median follow-up of 44.8 months, median DFS in the pembrolizumab arm was 29.6 months vs 14.2 months in the observation arm. After a median 45 months of follow-up, data indicate that adjuvant ...

Radium223 (Xofigo), a calcium mimetic radioactive therapy indicated to treat prostate cancer, may be a particularly beneficial symptom-treating therapy as a regimen prior to chemotherapy in patients ...